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Herpes zoster subunit vaccine for the prevention of herpes zoster 
Abstract 
Purpose Published literature on the efficacy and safety of the herpes zoster (HZ) subunit vaccine (HZ/su 
vaccine) in reducing the risks of HZ and postherpetic neuralgia (PHN) in adults 50 years of age and older, 
as well as the vaccine’s properties and efficacy relative to live attenuated vaccine, is reviewed. 
Summary HZ/su vaccine (Shingrix, GlaxoSmithKline) is a recently Food and Drug Administration 
(FDA)–approved vaccine indicated for the prevention of HZ in adults 50 years of age and older. Based on 
several Phase III trials, the Advisory Committee on Immunization Practices has preferentially 
recommended HZ/su vaccine over a live attenuated vaccine previously approved by FDA. Reported overall 
HZ/su vaccine efficacy in preventing HZ in Phase III trials ranged from 89.8% to 97.2%. Compared with 
placebo use, HZ/su vaccine in those trials was associated with higher rates of transient local and 
systemic adverse events (AEs) but similar rates of serious vaccine-related AEs. Other clinical trials of HZ/
su vaccine have yielded favorable results in various populations, including adults with a history of HZ, 
older adults who previously received live attenuated zoster vaccine, adults with human immunodeficiency 
virus infection, and stem cell transplant recipients. 
Conclusion HZ/su vaccine is a recently approved, preferred option to reduce the risks of HZ and PHN in 
adults 50 years of age or older. Pain at the injection site is the most common AE associated with use of 
the vaccine. 
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Pharmacy and Pharmaceutical Sciences 
Comments 
This is the authors' manuscript version of the article. The article was published in its final form by the 
American Society of Health-System Pharmacists and can be viewed here: https://doi.org/10.2146/
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Abstract 
Purpose. Review and evaluate the efficacy and safety of the herpes zoster subunit 
(HZ/su) vaccine in reducing the risk of herpes zoster (HZ) and postherpetic neuralgia 
(PHN) in adults 50 years of age and older, as well as, compare the vaccine properties 
and efficacy of HZ/su to the currently available zoster vaccine live. 
 
Summary. HZ/su (Shingrix™) is a newly Food and Drug Administration (FDA)-approved 
vaccine indicated to prevent HZ in adults 50 years of age and older. Based on several 
phase III trials, the Advisory Committee on Immunization Practices (ACIP) has 
preferentially recommended HZ/su over the previously available zoster vaccine live 
(Zostavax®). Overall vaccine efficacy for preventing HZ reported in phase III trials 
ranged from 89.8 to 97.2%. When studied against placebo, HZ/su was associated with 
a higher incidence of transient local and systemic adverse events (AE) but a similar 
amount of serious vaccine-related AE.  
 
Conclusion. A review of published literature demonstrates that the HZ/su vaccine is 
thought to be an improved alternative to zoster vaccine live in reducing the risk of HZ in 
adults 50 of years of age and older. 
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Key points 
• HZ/su is a novel vaccine that has proven efficacy in reducing the incidence of herpes 
zoster infection in patients 50 years of age and older in phase III clinical trials. 
• Unlike zoster vaccine live, HZ/su is a non-live recombinant vaccine administered 
intramuscularly in a two-dose series to be completed two to six months apart. 
• HZ/su safety data from phase III trials indicate similar rates of serious vaccine-related 
adverse events or death when compared to placebo. 
 
Keywords: Herpes zoster subunit vaccine (ShingrixTM), HZ/su, zoster vaccine live 
(Zostavax®), herpes zoster, postherpetic neuralgia, and shingles 
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Introduction 
The herpes zoster virus (HZV), commonly known as shingles, is a debilitating condition 
caused by reactivation of the varicella zoster virus (VZV). The initial infection presents 
as chickenpox, which typically occurs during childhood, and is characterized by viremia 
with diffuse rash and seeding of multiple sensory ganglia where the virus establishes 
lifelong latency.1 Although HZ can occur at any age, it is generally more prevalent and 
severe in older adults with higher rates of morbidity than seen in children and younger 
adults.1,2 There are more than one million cases of HZ each year in the United States.3 
According to claims data from a retrospective, observational, cohort study conducted in 
2011, the annual incidence rate of HZ in immunocompetent adult patients was 4.47 per 
1000 person-years (95% confidence interval [CI]: 4.44–4.50) across all ages. The rate 
for those 50 years and older was 8.46 (95% CI: 8.39-8.52), for those 60 years and older 
was 10.46 (95% CI: 10.35-10.56), and for those 80 years and older was 12.78 (95 % CI: 
12.49–13.07).4 These findings are consistent with other literature supporting that the 
rate of HZ increases with age.5 VZV reactivation increases with age due to a decline in 
immune response and a weakening of cell-mediated varicella virus specific T-cell 
activity over time.6 Postherpetic neuralgia (PHN) is one of the most common and painful 
outcomes associated with HZ, and occurs in 10-50% of patients with age increasing 
risk.1,7 Antiviral therapy has been shown to reduce some of the symptoms associated 
with HZ including rash, but it has not been shown to reduce the incidence of PHN, 
further complications, or disease burden in older adults.7 Vaccination against HZ has 
become standard care to reduce disease burden and its complications in older adults. 
The purpose of this literature review is to investigate the effectiveness of HZ/su in 
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reducing the risk of HZ and PHN in older adults. 
 
Methods 
A literature search was conducted through November 2017 using PubMed and Google 
Scholar to locate clinical trials and other relevant peer reviewed publications which 
evaluated HZ/su and zoster vaccine live. Search terms utilized were herpes zoster 
subunit vaccine, HZ/su, HIV and herpes zoster subunit, herpes zoster subunit and 
immunocompromised, zoster vaccine live, and Zostavax®. Additionally, clinicaltrials.gov, 
zoster vaccine recombinant adjuvanted prescribing information, and zoster vaccine live 
prescribing information as well as the websites for the Center for Disease Control and 
Prevention and GlaxoSmithKline (GSK) were utilized to obtain further information. 
Finally, references from identified articles were also reviewed for inclusion. Outcomes of 
select phase III clinical trials regarding HZ/su are summarized below. All trials reviewed 
were conducted in accordance with the Declaration of Helsinki and good clinical 
practice guidelines. While no published randomized, controlled phase III studies have 
directly compared HZ/su to zoster vaccine live up to this point, the properties and 
vaccine efficacy of both are reviewed. 
 
Zoster vaccine live and HZ/su background information 
Zoster vaccine live, an attenuated vaccine containing the Oka VZV strain, was the first 
FDA-approved method for HZ prevention in adults 50 years of age and older.8,9 It is 
administered as a one-time subcutaneous injection and must be given within 30 minutes 
of reconstitution. The mechanism of action of this vaccine is to boost the T-cell 
7 
 
mediated immunity to VZV and thereby provide protection against HZ and PHN. It was 
first approved in May 2006 for use in patients 60 years of age and older.10 In March 
2011, the FDA extended its indication for use to individuals 50 to 59 years of age; 
however, the Advisory Committee on Immunization Practices (ACIP) denied to 
recommend the vaccine for this patient population based on limited data demonstrating 
protection beyond five years.9 ACIP continues to recommend this vaccine for adults 
aged 60 years and older. 
 
Several clinical trials of zoster vaccine live have previously been conducted.9,11-15 
Results of the largest randomized, double-blind, placebo-controlled phase III trials, the 
Shingles Prevention Study (SPS) and the Zostavax Efficacy and Safety Trial (ZEST) 
can be found in Table 1.9,11 Since zoster vaccine live has been shown to be less 
effective in older age groups, and the efficacy of the vaccine wanes over time, a new HZ 
vaccine with improved protection against HZ in older adults that provides longer post-
vaccination efficacy is needed.  
 
HZ/su is a non-live herpes zoster subunit vaccine that incorporates VZV glycoprotein E 
(gE) and the AS01B adjuvant system.18 VZV gE antigen was selected because it is the 
most abundant glycoprotein on both VZV virions and cells infected with VZV. In 
addition, it plays a crucial role in virus replication and cell-to-cell spread while 
demonstrating a greater immune response when compared to other glycoprotein 
antigens.19 This antigen was combined with the AS01B adjuvant system because AS01B 
has been shown to enhance CD4+ T-cell and humoral immune response toward the 
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recombinant protein complex, particularly in older adults.16  
 
HZ/su must be used within six hours of reconstitution. The dose (0.5 mL) should be 
administered intramuscularly into the deltoid muscle. HZ/su is a two-dose series, the 
second dose should be given two to six months following the first dose.20 Each dose of 
HZ/su contains 50 µg of recombinant VZV gE and liposome-based AS01B adjuvant 
system containing 50 µg of 3-0-desacyl-4'-monophosphoryl lipid A (MPL) and 50 µg of 
Quillaja saponria Moilina, fraction 21.16 HZ/su does not contain preservatives.20 
 
Clinical efficacy trials for HZ/su 
Zoster Efficacy Studies (ZOEs) 
The efficacy and safety of HZ/su in preventing HZ has been investigated in two large 
randomized, triple-blinded, placebo-controlled, multicenter phase III clinical trials: Zoster 
Efficacy Study in Adults 50 Years of Age or Older (ZOE-50) and Zoster Efficacy Study in 
Adults 70 Years of Age or Older (ZOE-70).16,17 Study sites for both studies were in 18 
different countries in Europe, North America, Latin America, Asia, and Australia. 
 
ZOE-50 studied adults age 50 and older.16 Participants were randomized 1:1 to receive 
HZ/su or placebo and stratified according to the following age groups: 50 to 59 years, 
60 to 69 years, and 70 years and older. Each received two intramuscular doses of 
HZ/su, or placebo, two months apart. Notable exclusion criteria were history of HZ, prior 
vaccination again VZV or HZ, immunosuppression, receipt of immunoglobulin or blood 
product within the previous 90 days, receipt or planned administration of any other 
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immunization prior to or during the study period, and pregnancy or lactation. The 
primary outcome was vaccine efficacy in reducing the risk of HZ in the modified 
vaccinated cohort. The modified vaccinated cohort included all participants who 
received two doses of vaccine and did not have a diagnosis of HZ within one month of 
the second dose; whereas, the total vaccinated cohort included all participants who had 
at least one dose of study vaccine administered. Secondary outcomes were vaccine 
efficacy in reducing the incidence of HZ in each stratified age group and HZ/su safety 
and reactogenicity profiles. Safety and reactogenicity were evaluated via diary cards in 
a subgroup of participants that included all those 70 years of age and older and 
randomly selected participants from the other two age groups. Serious AE were 
recorded in all subjects for 12 months following the second dose of HZ/su. Participants 
were followed for at least 30 months through monthly contacts and annual visits.16 
 
Total enrollment, demographic characteristics, and main efficacy and safety findings are 
available in Table 1. Overall, HZ/su was found to reduce the risk of HZ by 97.2% (95% 
CI, 93.7-99.0) compared to placebo in the modified vaccinated cohort. Similarly, vaccine 
efficacy in the total vaccinated cohort overall was 96.2% (95% CI, 92.7-98.3) for HZ/su 
compared to placebo. No significant variations in vaccine efficacy between the age-
stratified groups in the modified vaccinated cohort were found.16  
 
Solicited safety and reactogenicity data reported for the subgroup are available in Table 
2; grade 3 reactions are provided below. Grade 3 solicited injection site reactions were 
reported in 417 out of 4,382 subjects (9.5%) in the HZ/su subgroup participants 
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compared to 16 out of 4,377 subjects (0.4%) in placebo subgroup participants, and 
grade 3 solicited systemic reactions were reported in 498 out of 4,375 (11.4%) of the 
HZ/su subgroup participants compared to 106 out of 4,378 (2.4%) in the placebo 
subgroup participants. Serious AE throughout the study period occurred in a similar 
percentage of vaccine and placebo recipients at 9.0% (689 out of 7,698) and 8.9% (686 
out of 7,713) respectively. Immune-mediated diseases were observed in 1.0% (n = 78) 
in the vaccine group and in 1.3% (n = 97) in the placebo group. Moreover, death 
occurred in 2.2% (n = 167) of the vaccine group and 2.3% (n = 174) of the placebo 
group during the study. Final results at 60 months were reported in a pooled analysis 
with ZOE-70 participants and are discussed below. The authors concluded that HZ/su 
significantly reduced the risk of HZ in adults 50 years of age compared to placebo, with 
similar efficacy among the three age groups. No safety concerns were identified but 
solicited injection site reaction did occur more frequently in the HZ/su group.16 
 
ZOE-70 was a separate parallel study conducted over the same time period as ZOE-
50.17 Even though 24% of subjects enrolled in ZOE-50 were 70 years of age and older, 
the trial was not specifically powered to assess the efficacy of HZ/su in that oldest age 
group. Therefore, ZOE-70 was designed to evaluate vaccine efficacy in reducing the 
risk of HZ in adults 70 years of age and older. Participants were randomized in a 1:1 
ratio to receive HZ/su or placebo and stratified according to continent and age (70 to 79 
and ≥ 80 years). Each received two intramuscular doses of HZ/su or placebo two 
months apart. Study population as well as exclusion criteria were identical to that for 
ZOE-50 except for age. The primary outcome was vaccine efficacy in reducing the risk 
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of HZ in patients 70 years of age and older via analysis of the modified vaccinated 
cohort. A pooled analysis including participants from ZOE-50 and ZOE-70 was 
conducted with the primary outcome of vaccine efficacy in reducing the risk of HZ and 
PHN in the overall population 70 years of age and older. The secondary outcomes for 
the pooled analysis were vaccine efficacy against PHN for patients age 50 and above 
and vaccine safety and reactogenicity. Safety and reactogenicity were evaluated in a 
subgroup via the same manner as in ZOE-50. Follow up for at least 30 months after the 
second vaccine dose via monthly contact in addition to annual clinic visits occurred.17  
 
Twenty-two percent (3,066 out of 13,900) of patients enrolled in ZOE-70 were ≥ 80 
years of age; 0.5% (n = 76) were ≥ 90 years of years. Overall vaccine efficacy was 
89.8% (95% CI, 84.2-93.7) for HZ/su as compared to placebo. There was no significant 
difference in vaccine efficacy between the two age groups, 90.0% (95% CI, 83.5-94.4) 
among adults 70 to 79 years of age (n = 5,114) and 89.1% (95% CI, 74.6-96.2) among 
adults 80 years of age and older (n = 1,427). In the pooled analysis of 8,250 subjects, 
vaccine efficacy was 91.3% (95% CI, 86.8-94.5%) in reducing the risk of HZ with no 
significant difference among adults 70 to 79 years of age (n = 6,468) and 80 years of 
age and older (n = 1,782) (91.3% [95% CI, 86.0-94.9] and 91.4% [95% CI, 80.2-97.0] 
respectively). Vaccine efficacy in the pooled cohort for each year through year four was 
determined at 97.6% (95% CI, 90.9-99.8) during year one (n = 8,250), 92.0% (95% CI, 
82.8-96.9%) during year two (n = 8,039), 84.7% (95% CI, 69.0-93.4%) during year three 
(n = 7,736), and 87.9% (95% CI, 73.3-95.4%) during year four (n = 7,426). Vaccine 
efficacy against PHN for the pooled modified vaccinated cohort of patients 50 years of 
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age and older (n = 13,881) was 91.2% (95% CI, 75.9-97.7%). PHN did not develop in 
any participants younger than 70 years of age in the HZ/su group. Vaccine efficacy 
against PHN for ≥ 70 years was 88.8% (95% CI, 68.7-97.1). The incidence of PHN in 
recipients of HZ/su that experienced breakthrough HZ did not differ significantly from the 
placebo recipients [12.5% (n = 4) vs. 9.6% (n = 36), P= 0.54].14 
 
Solicited safety and reactogenicity data reported for the subgroup can be found in Table 
2. Grade 3 solicited injection site reactions were reported in 43 out of 505 (8.5%) in the 
HZ/su subgroup participants compared to 1 out of 505 (0.2%) in placebo subgroup 
participants, and grade 3 solicited systemic reactions were reported in 30 out of 504 
(6.0%) in the HZ/su subgroup participants compared to 10 out of 505 (2.0%) in the 
placebo subgroup participants. Grade 3 reactions were transient, lasting less than 48 
hours. Serious AE throughout the study period occurred in a similar percentage of 
vaccine and placebo recipients at 16.6% (n = 1,153 out of 6,950) and 17.5% (n = 1,214 
out of 6,950) respectively. Immune-mediated diseases were observed in 1.3% (n = 92) 
in the vaccine group and in 1.4% (n = 97) in the placebo group. Death occurred in 6.1% 
(n = 426) and 6.6% (n = 459) in the HZ/su and placebo groups respectively. One 
participant death in the HZ/su group was determined by the investigators to be related 
to study intervention. A 90-year-old with pre-existing thrombocytopenia was diagnosed 
with acute myeloid leukemia 75 days after receipt the first HZ/su dose and died at 97 
days after that dose due to neutropenic sepsis. The authors concluded that HZ/su 
reduced the risk of HZ and PHN in adults 70 years of age and older with no substantial 
concerns for safety. Results of ZOE-70 are consistent with results from ZOE-50. 
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Authors caution that deductions regarding a potential lack of decline in efficacy of HZ/su 
over time cannot be made until additional follow up over a longer period becomes 
available.14  
 
While ZOE-50 and ZOE-70 were large, multicenter trials with a randomized, placebo-
controlled design, there are a few limitations to note. First, the number of participants 
that developed PHN was very low, none under 70 years of age, so there was limited 
power to evaluate the efficacy of HZ/su in reducing the risk of PHN overall. The reported 
decline in PHN cannot be directly supported by the study data but seems to be a result 
of the notable efficacy of HZ/su in preventing HZ reactivation. Second, mean follow up 
time was 3.2 and 3.7 years respectively; evidence that vaccine efficacy persists over a 
longer duration is needed. Finally, the studies excluded those with a history of HZ, 
previous varicella or zoster vaccination, immunosuppression, and pregnancy. These 
patient populations may benefit from an adjuvanted vaccine since zoster vaccine live is 
contraindicated in these situations.  
 
The studies summarized below all utilized increases in HZV-specific anti-gE antibodies 
as endpoints. VZV gE is the most abundant glycoprotein in VZV viral particles and cells 
infected with VZV. VZV gE plays a central role in virus infectivity, cell-to-cell spread, and 
progression of the infection.21 Therefore anti-gE antibodies are thought to be predictors 
of disease. The threshold at which anti-gE antibody response correlates to disease 
prevention is unclear so the use of this surrogate marker predicts immune response to 
HZ/su but has not been quantitatively correlated to disease prevention. 
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Use in patients with a history of HZ 
An open-label, nonrandomized, multicenter phase III study evaluated the 
immunogenicity and safety of HZ/su in adults aged 50 years or older with a documented 
history of HZ.22 Exclusion criteria were active HZ infection, prior vaccination for VZV or 
HZ, and any confirmed or suspected immunosuppressive condition. HZ/su was 
administered in two doses, given two months apart. The primary endpoint for 
immunogenicity was vaccine response rate, defined as increasing anti-gE antibodies 
four times above baseline, with an objective to meet the lower limit of the 95% CI at 
three months at or above 60%. Participants were followed for 12 months after vaccine 
administration. Total enrollment was 96 participants. Most (67.7%) reported having HZ 
within the previous four years. Median age was 64 (range 50-89) years. Vaccine 
response rate at three months was 90.2%, which met the prespecified immunogenicity 
endpoint. Local solicited AE occurred in 77.9% of participants whereas 71.6% of 
participants experienced general solicited AE. Although there was no comparator group, 
authors concluded that HZ/su was immunogenic with no safety concerns in this study 
population of adults at least 50 years of age and a history of physician-documented 
HZ.22  
 
Use in patients who were previously vaccinated with zoster vaccine live  
An open-label, multicenter phase III study of adults aged 65 years and older compared 
the use of HZ/su in subjects previously vaccinated with zoster vaccine live (at least 5 
years prior) to matched subjects unvaccinated against HZ.23 Groups were matched on 
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age, gender, race, and medical conditions. Major exclusion criteria were a history of HZ 
and immunosuppression. The co-primary objectives were non-inferiority of humoral 
immune response, measured by anti-gE antibody geometric mean concentration 
(GMC), and safety and reactogenicity at one month following dose two. There were 430 
participants enrolled, all received two doses of HZ/su two months apart. Mean age was 
70.9 (SD 4.6) years and 51.2% were female. Humoral immune response to HZ/su was 
non-inferior in those that previously received zoster vaccine live and those that were not 
previously vaccinated against HZ (adjusted anti-gE antibody GMC ration of 1.04, 95% 
CI 0.92-1.17). Reactogenicity and safety were similar between groups. Solicited AE 
were transient with a median duration of three days or less. Local reaction occurred in 
193 of 215 (89.8%) participants who previously received zoster vaccine live and 187 of 
214 (87.4%) participants without previous vaccination. Authors concluded that HZ/su 
induced strong immune response and was well tolerated regardless of prior vaccination 
against HZ with zoster vaccine live. Therefore HZ/su may be an attractive option to use 
for re-vaccination of those who previously received zoster vaccine live. 
 
Use in patients with HIV 
The safety and immunogenicity of HZ/su in HIV-infected adults was evaluated in a 
randomized, observer-blinded, placebo-controlled multicenter phase 1/2a study.24 
Eligible subjects had a diagnosis of HIV for at least a year. Those with an episode of 
VZV or HZ or receipt of vaccination against either virus within the prior 12 months; 
ongoing treatment with HIV fusion inhibitors, CCR5 inhibitors, or interleukin 2/interleukin 
7/interferon gamma; or an opportunistic infection other than oral thrush within the 
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previous year were excluded. It was unknown whether the standard two-dose regimen 
would elicit a favorable immune response in HIV-infected individuals, therefore three 
doses were administered and immunogenicity was evaluated after doses two and three. 
The co-primary objectives were to evaluate gE-specific humoral and cellular immune 
responses one month following the third vaccination in the HZ/su group compared to the 
placebo group, and safety and reactogenicity. Serious AE, new onset of immune-
mediated inflammatory diseases, worsening HIV, and HZ were reported throughout the 
study. Subjects were randomized in a 3:2 ratio to receive HZ/su or placebo at months 
zero, two, and six.24  
 
Three cohorts of HIV-infected adults were enrolled: 94 with a CD4+ count of ≥ 200 
cells/mm3 and receiving antiretroviral therapy (ART),14 with a CD4+ count of 50-199 
cells/mm3 on ART, and 15 ART-naive adults with a CD4+ count of ≥ 500 cells/mm3. 
Mean age was 46.0 (SD 10.93) years (n = 123), 94.3% (n = 116) of patients were male, 
and 87.8% (n = 108) were White. Due to widespread use of ART, enrollment for the 
ART-naive and ART/low CD4+ count cohorts was lower than anticipated and had low 
statistical power. Therefore, efficacy analyses were reported for the pooled ART/high 
CD4+ count and ART-naive cohorts. One month after the third vaccination, CD4+ cell 
markers of cell-mediated immunity and gE-specific humoral immune response were 
higher in the HZ/su group than in the placebo group (p<0.0001 for both). Both cell-
mediated and humoral immune responses persisted through 18 months when the study 
was completed.24  
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Local and systemic reactions were common among HZ/su recipients. Pain at injection 
site was reported in 72 of 73 patients (98.6%) in the HZ/su group and in 6 of 48 patients 
(12.5%) of the placebo group. Most local and systemic reactions were transient (median 
duration one to three days) in the HZ/su group. No vaccine-related serious AE, or new 
onset immune-related inflammatory diseases were reported. Through month seven, 
12.2% (9 out of 74) in the HZ/su group and 10.2% (5 out of 49) in the placebo group 
met protocol-defined criteria for a possible worsening of HIV disease. One subject in the 
HZ/su group reported HZ 83 days after the first dose. Authors concluded that HZ/su 
elicited a strong gE-specific cellular and humoral response with a clinically acceptable 
safety profile in HIV-infected individuals after two doses. The third dose did not add 
much, if any, immunological advantage.24 
 
Use in patients following stem cell transplant 
The safety and immunogenicity of HZ/su was investigated in a randomized, observer-
blinded, placebo-controlled phase 1/2a study conducted in adults who underwent 
autologous HCT.25 Subjects with a history of multiple myeloma, non-Hodgkin lymphoma 
(B- or T-cell), Hodgkin lymphoma, or acute myeloid leukemia with an autologous HCT in 
the previous 50-70 days were eligible. Major exclusion criteria were previous receipt of 
VZV or HZ vaccine, history of HZ within 12 months prior to enrollment, known exposure 
to VZV post-transplant, receipt of vaccinations (other than inactivated influenza vaccine) 
or immunoglobulins since transplantation, and woman of childbearing potential. The 
study compared four groups, one placebo group and three separate active treatment 
groups. In the first active arm subjects received three doses of 50 µg gE + AS01B, in the 
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second subjects received three doses of 50 µg gE + AS01E, and in the third subjects 
received one dose of saline followed by two doses of 50 µg VZV gE + AS01B. Study 
vaccine was administered at months zero, one, and three. The co-primary objectives 
were to examine the safety and immunogenicity of the two adjuvanted gE subunit 
vaccine formulations (AS01B and AS01E) in the autologous HCT population and to 
compare gE-specific immune responses one month following final vaccination between 
the four groups. Recurrence of underlying malignancy and new onset autoimmune 
disease or immune-mediated inflammatory disorders were recorded for the duration of 
the study. Participants were randomized 1:1:1:1.25  
 
A total of 121 participants were enrolled. Median participant age was 59.0 years (range 
20-70), 65% were male, and 83.3% were White. One month after receipt of the final 
dose, cellular and humoral immune responses were higher in all three gE/AS01 groups 
compared to placebo (p< 0.0001 for all comparisons). Although there were no statistical 
differences in immunity between the AS01B and AS01E groups, AS01B tended to be 
more immunogenic. Immune responses persisted up to one year post-vaccination.25  
 
Most subjects in the HZ/su groups experienced solicited local and general reactions. 
Pain at the injection site was the most commonly reported local reaction (75.9-90.0% in 
the three groups which received HZ/su compared to 13.3-23.3% in placebo recipients) 
while myalgia (62.1-78.6% in the HZ/su recipients compared to 26.7-30% in placebo 
recipients) was the most commonly reported general reaction. One serious AE was 
potentially related to the vaccination according to the study investigator. It was 
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pneumonia which occurred 105 days after the second dose in the gE/AS01B two-dose 
group. Malignancy recurred in 32 subjects. No new onset autoimmune diseases or 
immune-mediated inflammatory diseases were reported. Although there were nine 
deaths during the study period none were considered to be related to vaccination. 
Throughout the study, four cases of HZ were confirmed, two in the gE/AS01E group and 
two in the placebo group. Five subjects withdrew from the study due to serious AE. 
Authors’ conclusions were that both adjuvanted vaccine formulations and both AS01B 
schedules were immunogenic and well tolerated soon after HCT in this 
immunocompromised patient population. The vaccine may be a suitable candidate to 
reduce HZ burden in autologous HCT recipients.25 
 
Current regulatory status 
On October 24, 2016, GSK Vaccines Division announced regulatory submission of a 
Biologics License Application for the candidate vaccine HZ/su (ShingrixTM).10 GSK also 
filed a marketing authorization application in the European Union and Canada in 2016 
and in Japan in April 2017.26-27 In early October 2017, HZ/su was approved in Canada 
for the prevention of HZ in adults 50 years of age and older.28 On October 20, 2017, the 
FDA approved HZ/su for the prevention of HZ in adults aged 50 years and older.29 The 
CDC’s ACIP subsequently voted to recommend HZ/su to prevent HZ and related 
complications in immunocompetent adults aged 50 years and older, including those who 
were previously vaccinated with zoster vaccine live. Furthermore, the group voted to 
prefer HZ/su over zoster vaccine live moving forward.30 
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Discussion 
Studies summarized above have shown that HZ/su effectively decreases the risk of HZ 
(overall vaccine efficacy in reported phase III trials ranged from 89.8-97.2%) in older 
patients, including those > 80.16,17,22 Available evidence has not shown a substantial 
decline in immune response to HZ/su in older age over time (97.6% in year one to 
87.9% in year four following administration) but longer-term evaluation is needed.17 
 
PHN is considered to be a large burden associated with HZ, especially in older patients. 
All patients that developed PHN in pooled data from ZOE-50 and ZOE-70 were over the 
age of 70, but the incidence was low.17 The overall risk of PHN was reduced in patients 
who received HZ/su, but the protective effect against PHN may have been driven by the 
lower overall incidence of HZ due to high vaccine efficacy. There is no evidence for 
additional efficacy for the vaccine against PHN among HZ/su recipients who had 
breakthrough HZ, but the overall risk of developing PHN among older adults was 
substantially reduced.   
 
While no direct head-to-head trials evaluating vaccine efficacy of HZ/su compared to 
zoster vaccine live have been published to date, in separate phase III trials, HZ/su 
seems to have better efficacy in those older than 70 years of age, higher efficacy for the 
prevention of PHN, and potentially longer persistence of immunogenicity. However, 
direct comparison of efficacy results of HZ/su and zoster vaccine live in phase III clinical 
trials is difficult as the primary endpoints were different for the trials. A head-to-head trial 
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comparing HZ/su to zoster vaccine live in individuals 50-59 and 70-85 years of age is 
ongoing (NCT02114333).31 
 The results will provide greater insight in determining differences in efficacy between 
HZ/su and zoster vaccine live.  
 
When compared to placebo, reactogenicity of HZ/su was greater in all studies. Although 
pain at the injection site was the most common solicited AE reported in the HZ/su 
treatment groups, most reactions were transient and considered to be mild to moderate 
in nature.16,17,22 Safety data demonstrated no significant differences in rates of vaccine-
related serious AE or death between HZ/su and placebo.  
 
Place in therapy 
Newly approved by the FDA, HZ/su is expected to have an expanded role in therapy 
compared to zoster vaccine live and is being endorsed by the ACIP as the preferred 
vaccination against HZ. Because HZ/su is a two dose series, completion of the second 
dose will need to be reinforced.  
 
The efficacy and safety of HZ/su in immunocompromised patients has been 
demonstrated in two small studies with limited patient populations but additional trials 
are ongoing. A placebo-controlled, phase III trial examining the efficacy and safety of a 
two-dose schedule of HZ/su in adults following HCT has completed enrollment and is 
awaiting results (NCT01610414).32 Another placebo-controlled, phase III trial is 
evaluating the use of HZ/su in adult renal transplant patients (NCT02058589).33 The 
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results of these studies may lead to approval of HZ/su for immunocompromised 
populations where a gap in protection currently exists. 
 
Conclusion 
The risk and severity of HZ increase with age and immunosuppression. Zoster vaccine 
live has been available for over a decade. However, it has limitations including lower 
efficacy in patients older than 60 years, a decline in efficacy over time, and a 
contraindication in immunocompromised patients. HZ/su is a new and preferred option 
to reduce the risk of HZ and PHN in patients 50 years of age and older. It has 
advantages over zoster vaccine live and in the future may be appropriate for 
immunosuppressed patients. 
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Table 1. Summary of major phase III clinical trials for zoster vaccine live and HZ/sua 
 SPS11 ZEST9 ZOE-5016 ZOE-7017 
Vaccine 
complex 
studied 
Live attenuated 
(Oka/Merk strain) 
Live attenuated (Oka/Merk 
strain) 
Non-live recombinant 
subunit (HZ/su) 
Non-live recombinant 
subunit (HZ/su) 
Study 
population 
Adults 60 years of 
age or older with a 
history of VZV but no 
history of  HZ or 
vaccination against 
VZV 
Adults 50-59 years of age 
with a history of VZV but 
no history of  HZ or 
vaccination against VZV 
Adults 50 years of age 
or older with no history 
of  HZ or vaccination 
against VZV or HZ 
Adults 70 years of age 
or older with no history 
of HZ or vaccination 
against VZV or HZ 
Study follow 
up for efficacy 
(mean 
number of 
years) 
3.12 (median) 1.3 3.2 3.7 
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Total number 
of patients (n) 
38,546 22,439 15,411 13,900 
Treatment 
group, for 
population 
evaluated in 
primary 
objective (n) 
19,270 11,211 7,698 6,950 
Placebo 
group (n) 
19,276 11,228 7,713 6,950 
Mean age ± 
SD (years) 
69 (median) 54.9 ± 2.8 62.3 ± 9.0 75.6 ± 4.7 
Male (%) 59 [n = 22, 760] 38 [n = 8,554] 38.8 [n = 5,987] 45.1 [n = 6,275]  
White race 
(%) 
95.4 [n = 36,774] 94.4 [n = 21,189] 71.8 [11,067] 76.9 [n = 10,695] 
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Vaccine 
efficacy in 
reducing risk 
of HZ (%) 
Overall study 
population = 51.3, 
subjects aged 60-69 
= 63.9%, and 
subjects aged ≥ 70 = 
37.6% (p<0.001 for 
all) 
69.8 (95% CI, 54.1-80.6) Overall modified 
vaccinated cohort 
analysis = 97.2 (95% 
CI 93.7-99.0), subjects 
aged 50-59 = 96.6 
(95% CI 89.6-99.3), 
subjects 60-69 = 97.4 
(95% CI 90.1-99.7), 
subjects aged ≥ 70 = 
97.9 (95% CI, 87.9-
100.0) 
89.8 (95% CI, 84.2-
93.7%) 
Vaccine 
efficacy in 
reducing risk 
of PHN (%) 
66.5 (95% CI, 47.5-
79.2%) 
Not evaluated Pooled analysis 
evaluated in ZOE-70, 
see next column 
Pooled analysis from 
ZOE-50 and ZOE-70, 
subjects ≥ 70 = 88.8 
(95%, 68.7-97.1%) 
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Vaccine-
related 
serious 
adverse 
events 
reported in 
vaccine group 
(%) 
< 0.1 [n = 2] 0 [n = 1] 0 [n = 1] 0.2 [n = 12] 
Vaccine-
related 
serious 
adverse 
events 
reported in 
placebo group 
(%) 
< 0.1 [n = 3] 0 [n = 0] 0 [n = 3] 0.1 [n = 8] 
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aHZ/su = herpes zoster subunit, SPS = Shingles Prevention Study, ZEST = Zostavax Efficacy and Safety Trial, ZOE-50 = 
Zoster Efficacy Study in Adults 50 Years of Age and Older, ZOE-70 = Zoster Efficacy Study in Adults 70 Years of Age and 
Older, VZV = varicella zoster virus, HZ = herpes zoster, US = United States, PHN = postherpetic neuralgia 
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Table 2. Safety and reactogenicity results within seven days of vaccination from the 
reactogenicity subgroups in key Phase III trials evaluating HZ/sua 
 ZOE-5016 ZOE-7017 
 HZ/su [n = 
4382] (%) 
Placebo [n = 
4377] (%) 
HZ/su [n = 505] 
(%) 
Placebo [n = 
505] (%) 
Injection site 
reaction 
81.5 (n = 3571) 11.9 (n = 522) 74.1 (n = 374) 9.9 (n = 50) 
Pain 79.1 (n = 3464) 11.2 (n = 490) 68.7 (n = 347) 8.5 (n = 43) 
Redness 38.0 (n = 1664) 1.3 (n = 59) 39.2 (n = 198) 1.0 (n = 5) 
Swelling 26.3 (n = 1153) 1.1 (n = 46) 22.6 (n = 114) 0.4 (n = 2) 
Systemic 
reaction 
66.1 (n = 2894)  29.5 (n = 1293) 53.0 (n = 267)  25.1 (n = 127) 
Fatigue 45.9 (n = 2008)  16.6 (n = 728) 32.9 (n = 166) 15.2 (n = 77) 
Myalgia 46.3 (n = 2025) 12.1 (n = 530) 31.2 (n = 157) 8.1 (n = 41) 
Headache 39.2 (n = 1716) 16.0 (n = 700) 24.6 (n = 124) 10.9 (n =55) 
Shivering 28.2 (n = 1232) 5.9 (n = 259) 14.9 (n = 75) 4.4 (n = 22) 
Fever 21.5 (n = 939) 3.0 (n = 132) 12.3 (n = 62) 2.6 (n = 13) 
GI symptoms 18.0 (n = 788) 8.8 (n = 106) 10.9 (n = 55) 7.9 (n = 40) 
aHZ/su = herpes zoster subunit, ZOE-50 = Zoster Efficacy Study in Adults 50 Years of 
Age or Older, ZOE-70 = Zoster Efficacy Study in Adults 70 Years of Age or Older, GI = 
gastrointestinal   
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